Jazz Pharmaceuticals Public Limited Company (JAZZ)

Jazz Pharmaceuticals' stock has been influenced by several events in the past six months. Positive Phase 3 data for Ziihera (zanidatamab) in HER2-positive GEA led to a stock surge, while mixed results from the HERIZON-GEA-01 trial caused a decline. Analyst ratings and price targets were adjusted by Piper Sandler, UBS, and Needham. The company missed Wall Street's revenue expectations for Q1 2025, and company insiders sold shares worth approximately $21.99 million in the last quarter of 2025.

Specific detailed information regarding the demand seasonality for Jazz Pharmaceuticals Plc's products and services is not readily available in public search results without requiring a login to specialized platforms. However, general trends indicate that while the company's annualized revenue growth has slowed over the last two years compared to its five-year trend, specific products can still experience demand-driven increases. For example, in Q3 2025, Xywav volumes increased by 10% due to demand. This suggests that demand for individual products may fluctuate based on factors such as new patient adds and market dynamics, rather than strict seasonal patterns.

Jazz Pharmaceuticals Plc is a global biopharmaceutical company focused on identifying, developing, and commercializing innovative medicines for serious diseases in neuroscience and oncology. Headquartered in Dublin, Ireland, its product portfolio includes treatments for narcolepsy, idiopathic hypersomnia, seizures associated with severe epilepsy syndromes, acute lymphoblastic leukemia, lymphoblastic lymphoma, metastatic small cell lung cancer, and acute myeloid leukemia. Key products include Xyrem, Xywav, Epidiolex, Rylaze, Zepzelca, Vyxeos, and Ziihera.

Jazz Pharmaceuticals has a significant commercial and operational presence across Europe, North America, and Australia. The company is actively expanding into Japan and collaborates with other companies to bring its medicines to patients in regions such as Asia Pacific and Latin America. Jazz Pharmaceuticals operates world-class facilities, including manufacturing centers, in the U.S., U.K., Ireland, and throughout Europe.

Jazz Pharmaceuticals' brand reputation has been shaped by historical challenges and recent positive developments. While the company pleaded guilty to felony charges related to the marketing of Xyrem in 2007, its reputation has recently benefited from its commitment to innovation and patient care. Positive Phase 3 data for Ziihera (zanidatamab) in HER2-positive GEA has enhanced the company's standing in the oncology field. Jazz Pharmaceuticals emphasizes its mission to improve patients' lives and focuses on corporate sustainability and social impact.

Jazz Pharmaceuticals Plc has a high level of institutional ownership, with institutions holding approximately 88.86% to 98.87% of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Dimensional Fund Advisors Lp, Capital World Investors, Lsv Asset Management, State Street Corp, Jpmorgan Chase & Co, EcoR1 Capital, Fuller & Thaler Asset Management, and Columbia Threadneedle Investments (US). Individual ownership accounts for a smaller percentage, around 3.61%. Insider selling by company directors and officers was noted in the last quarter of 2025.